Laurus Labs Ltd. · NSE:LAURUSLABS
Laurus Labs — Q2 FY2026 Earnings Presentation
28 slides from Laurus Labs's earnings presentation, Oct 23, 2025
Slide 1: Cover letter to stock exchanges
October 23, 2025 To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS Dear Sir / Ma
Slide 2: Q2 & H1-FY 2026 Financial Results
Q2 & H1-FY 2026 Financial Results 23/10/2025 © 2025 Laurus Labs Ltd.
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. W
Slide 4: Agenda
Agenda 1 Q2 & H1 FY 2026 Corporate Overview 2 Q2 & H1 FY 2026 Financial Overview 3 Q2 & H1 FY 2026 Business Review & Strategy © 2025 Laurus Labs Ltd. Q2 & H1 - FY26 Results Presentation 23/10/2025 3
Slide 5: Corporate Overview
1 Corporate Overview Q2 & H1 FY 2026 4
Slide 6: Executive Summary
Executive Summary • Strong H1 performance ; ₹ 3,223 Cr Revenues and 33% revenues growth • Multiple CDMO programs in execution covering complex chemistries, supported by Generics growth • ₹ 818 Cr EBITDA resulted in a margin of 25.4%, increased by 10.8% pts, due to improving operational execution • D
Slide 7: Other Q2 Material updates
Other Q2 Material updates Significant Investment to secure Future growth 532 >US $600mn • Announced allotment of 532 acres land on 27 July 2025 by Acres of Land allotted; Government of Andhra Pradesh (India) in Vizag to create state- of Investment proposed over 2x bigger than existing land next 8 ye
Slide 8: Sustained recovery in asset turnover since mid-FY25 and resilient margins
Sustained recovery in asset turnover since mid-FY25 and resilient margins (~6 Quarters) • Successful CDMO deliveries across scales & 1.5x - Long lead times for - High value CDMO improvement in capacity efficiency driving continued 54% Complex CDMO project deliveries and recovery in asset turns at ex
Slide 9: Ongoing strategic investment to drive long term profitable growth
Ongoing strategic investment to drive long term profitable growth • >85% Growth CAPEX across API / CDMO CAPEX Project Mix Phase-wise Split of Investments portfolio supported by integrated Drug product approach 10% 23% • Dedicated CMO oral dosage capacity expansion on track 36% ~ ₹ 3,600 Cr 1 Total C
Slide 10: Integrated 'D & M' platform & Expanding Capabilities to support Global customers
Integrated ‘D & M’ platform & Expanding Capabilities to support Global customers R&D center Small Molecules R&D with Kilo lab, Hyderabad Unit 1 & 3, Vizag 3600 KL DS/DP Development 1 API/DS Manufacturing 1 2 3 4 5 6 8000 KL Reactors volumes New R&D, Hyderabad Unit 5, Vizag 161 KL DS Development 1 DS
Slide 11: Advancing ESG agenda and Enhancing competitive advantage
Advancing ESG agenda and Enhancing competitive advantage S&P Global ESG Score 73 Inclusion in S&P Global Sustainability Committed to Near- Improved S&P ESG Consecutive “BBB” Yearbook 2025 & term GHG targets Score Vs. 59/100 LY ratings in FY22-25 Only company to be Named “Industry Mover” from Pharma
Slide 12: Financial Overview
2 Financial Overview Q2 & H1 FY 2026 11
Slide 13: 1H FY26: Sustained strong performance
1H FY26: Sustained strong performance 1H FY26 Financial Summary Comments [₹ Crore] 1H FY26 1H FY25 Y-o-Y • Revenues : ₹ 3,223 Cr, increased 33% driven by healthy growth across both CDMO and Generics division Revenues 3,223 2,419 33% • Gross Margins : 59.6%, increased by 450 bps on better divisional
Slide 14: 1H FY26: CDMO execution remain strong, supported by Generics growth
1H FY26: CDMO execution remain strong, supported by Generics growth 1H FY26 Divisional Revenue Performance 1H FY26 Divisional Mix [₹ Crore] 1H FY26 1H FY25 Y-o-Y CDMO 1,040 596 74% 29% 30% CDMO 32% Small molecules 964 513 88% / +7% over last year Bio 76 83 -8% Generics 68% / -7% over last year ₹ 3,2
Slide 15: 2Q FY26: Revenue and Profit achieved strong growth
2Q FY26: Revenue and Profit achieved strong growth 2Q FY26 Financial Summary Comments [₹ Crore] 1Q FY26 2Q FY26 2Q FY25 Y-o-Y Q-o-Q • Revenues : ₹ 1,653 Cr, increased 35% primarily driven by robust CDMO performance supported by Generics growth (both FDF & API business) Revenues 1,570 1,653 1,224 35%
Slide 16: 2Q FY26: Sustained momentum across CDMO & Generics business
2Q FY26: Sustained momentum across CDMO & Generics business 2Q FY26 Divisional Revenue Performance 2Q FY26 Divisional Mix [₹ Crore] 1Q FY26 2Q FY26 2Q FY25 Y-o-Y Q-o-Q CDMO 522 518 339 53% -1% 28% CDMO 31% Small molecules 493 471 299 58% -4% 32% / +4% over last year Bio 29 47 40 18% 62% Generics 69%
Slide 17: Summary Quarter Performance: Acceleration in growth momentum
Summary Quarter Performance: Acceleration in growth momentum EBITDA & Gross Profit Margins Revenues [₹ Cr] 900 [₹ Cr] 59.4% 59.9% GPM 55.1% 55.2% 56.9% 58.0% 54.3% 54.5% 800 1,720 49.8% 1,653 700 48.0% 1,570 600 1,440 1,415 27.7% 38.0% 24.8% 26.0% OPM 500 1,195 1,195 1,224 400 18.0% 20.1% 28.0% 300
Slide 18: Business Review & Strategy
3 Business Review & Strategy Q2 & H1 FY 2026 17
Slide 19: CDMO – Small molecules: Continued growth across scale and offerings
CDMO – Small molecules: Continued growth across scale and offerings Revenue Growth Comments [₹ Cr] Y-o-Y ▲ 58% • Strong demand in complex small molecule offerings Q-o-Q ▼ 4% supporting expansion of project funnel with healthy mix of big / +88% mid pharma clients 964 • Continued strong growth >55% dr
Slide 20: Bio – Healthy recovery, Focus continues on building robust pipeline
Bio – Healthy recovery, Focus continues on building robust pipeline Revenue Growth Comments [₹ Cr] Y-o-Y ▲ 18% • Sequential revenue increase >60% with majority growth from de- Q-o-Q ▲ 62% risked customer base/commercial products. Focus continued on -8% building strong and diversified pipeline 83 76
Slide 21: Generics – Consistent execution with a Focus on Portfolio expansion
Generics – Consistent execution with a Focus on Portfolio expansion Revenue Growth Comments [₹ Cr] Y-o-Y ▲ 28% • FDF revenues increased > 50%, primarily driven by continued +20% Q-o-Q ▲ 8% uptake in ARV volumes, further supported by Developed market supplies. Continuing on calibrated portfolio expan
Slide 22: Cell, Gene and Other Advanced modalities - Updates
Cell, Gene and Other Advanced modalities - Updates Cell therapy Gene therapy & ADC capabilities • NexCAR19 Continued demand > 500 infusions as on Sep’25. • Invested in ADC technology platform company Aarvik BCMA targeted Ph-1 dosing ongoing for r/r Multiple Myeloma Therapeutics to advance integrated
Slide 23: R&D platform: Advancing Sustainable technology and Capability extension
R&D platform : Advancing Sustainable technology and Capability extension Significant Updates • Accelerating position on Flow/Bio-catalysis platform. Executed ton-level >75 R&D project* supported in FY25 project utilizing proprietary designed flow reactors at high temp/pressure • CDMO R&D facility op
Slide 24: Maintain the Global standard Quality systems
Maintain the Global standard Quality systems “One Quality Standard for all Markets” 1330+ Quality audits & Inspection Global Customers, Regulatory Last US FDA inspection Authorities since inception Key Key Regulatory # audits (since Date EIR Status Facilities Certifications inception) 54 Inspection
Slide 25: Outlook FY 2026 – Continuing H1 underlying momentum
Outlook FY 2026 – Continuing H1 underlying momentum • Revenue drivers - Continued robust CDMO industry outlook, Clinical and Commercial business momentum and Ramp-up of Growth projects - Generics growth supported by CMO opportunities, stable ARV business • Margin drivers: Underlying EBITDA margins e
Slide 26: Appendix
Appendix Pinus Labs
Slide 27: Earnings call details
Earnings call details Laurus Labs Results Conference Call to be held on Thursday, 23 October 2025 at 5:00 PM IST Dial – In – Details Universal Dial-In +91 22 6280 1384 Click below to Express Join with India Local access Number +91 22 7115 8285 Diamond Pass Singapore +800 1012045 Click here to regist
Slide 28: Additional Information
Additional Information Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral